Table 2 Capmatinib safety overview NSCLC with METex14 skipping mutation (GEOMETRY mono-1)
From: Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
| Adverse events | Cohort 4 (N = 69) | Cohort 5b (N = 28) | ||
|---|---|---|---|---|
| Total | Grade 3 or 4 | Total | Grade 3 or 4 | |
| Any event-no (%) | 68 (99) | 52 (75) | 28 (100) | 21 (75) |
| Peripheral edema | 37 (54) | 10 (14) | 21 (75) | 3 (11) |
| Nausea | 31 (46) | 0 | 13 (46) | 0 |
| Vomiting | 18 (26) | 0 | 7 (25) | 0 |
| Creatinine increased | 23 (33) | 0 | 10 (36) | 0 |
| Dyspnea | 19 (28) | 7 (10) | 6 (21) | 2 (7) |
| fatigue | 18 (26) | 6 (9) | 4 (14) | 1 (4) |
| Decreased appetite | 15 (22) | 1 (1) | 8 (29) | 0 |
| Constipation | 10 (14) | 2 (3) | 4 (14) | 0 |
| Diarrhea | 12 (17) | 0 | 5 (18) | 0 |
| Cough | 10 (14) | 1 (1) | 7 (25) | 0 |
| Back pain | 11 (16) | 2 (3) | 4 (14) | 0 |
| Pyrexia | 9 (13) | 1 (1) | 2 (7) | 0 |
| ALT increased | 8 (12) | 6 (9) | 4 (14) | 2 (7) |
| Asthenia | 6 (9) | 3 (4) | 4 (14) | 2 (7) |
| Pneumonia | 7 (10) | 4 (6) | 2 (7) | 0 |
| Weight loss | 9 (13) | 0 | 3 (11) | 0 |
| Non-cardiac chest pain | 5 (7) | 1 (1) | 1 (4) | 0 |
| Serious AE | 36 (52) | 30 (43) | 14 (50) | 12 (43) |
| Event leading to discontinuation | 14 (20) | 8 (12) | 6 (21) | 5 (18) |